• If you are wondering whether Eli Lilly stock still offers reasonable value after its huge run, this article will walk through what the current price might be implying.
• The stock trades around US$1,122.50, with returns of 11.7% over the past month, 3.9% year to date, 42.9% over the past year, very large gains over three years and around 7x over five years. This naturally raises questions about growth expectations and risk.
• Recent headlines around Eli Lilly have centered on its position in high profile therapeutic areas and the expectations built into obesity and diabetes treatments, which many investors closely monitor. At the same time, broader coverage has focused on how large cap pharmaceuticals are being priced compared with their product pipelines and regulatory environments, helping frame the current moves in the stock.
• Eli Lilly currently has a valuation score of 2/6, which suggests that only some traditional checks flag the stock as undervalued. The next sections will walk through common valuation methods and then finish with a broader way to think about what that means for you as an investor.

Eli Lilly scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Eli Lilly Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model estimates what Eli Lilly stock might be worth by projecting future cash flows and discounting them back to today, so you can compare that value with the current share price.

Eli Lilly reports last twelve month Free Cash Flow of about $8.6b. Analysts and model estimates project Free Cash Flow rising to around $48.7b by 2030, with a series of ten year projections that are discounted back using a 2 Stage Free Cash Flow to Equity approach. These projections, all in $, are combined to calculate an estimated intrinsic value per share of about $1,464.84.

Compared with a current share price of roughly $1,122.50, this DCF output indicates Eli Lilly is trading at a discount of about 23.4%, which means the stock screens as undervalued on this model alone.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Eli Lilly is undervalued by 23.4%. Track this in your watchlist or portfolio, or discover 44 more high quality undervalued stocks.

Approach 2: Eli Lilly Price vs Earnings

For profitable companies like Eli Lilly, the P/E ratio is often a useful shorthand because it links what you pay for the stock to the earnings the business is currently generating.

What counts as a “normal” P/E depends on how fast earnings are expected to grow and how risky those earnings might be. Higher expected growth or lower perceived risk can support a higher multiple, while slower growth or higher risk tend to line up with a lower multiple.

Eli Lilly currently trades on a P/E of about 39.6x, compared with an average of around 15.1x for the Pharmaceuticals industry and about 23.6x for its peer group. Simply Wall St’s Fair Ratio for Eli Lilly is 35.6x, which is its estimate of an appropriate P/E once factors such as earnings growth, margins, size, risks and industry are taken into account.

This Fair Ratio is more tailored than a simple comparison with peers or the broad industry because it adjusts for company specific characteristics rather than assuming a one size fits all multiple. On this framework, Eli Lilly’s actual P/E is higher than the Fair Ratio, which points to the stock looking overvalued on this measure.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Eli Lilly Narrative

Earlier it was mentioned that there is an even better way to understand what valuation models imply, and on Simply Wall St that comes through Narratives. These are investor written stories that tie a view on Eli Lilly’s products, risks and market opportunity to a set of explicit assumptions about future revenue, earnings, margins and an estimated fair value. That figure is then compared with the current share price to help decide whether the stock looks attractive or stretched.

Each Narrative connects this story directly to a financial forecast and a Fair Value number. This allows you to see, for example, how one Eli Lilly Narrative on the Community page might lean bullish with fair value around US$1,500 based on higher growth and margins, while another takes a more cautious stance closer to US$900 using lower growth and tighter pricing. Both views update automatically as new earnings, trial results or pricing news are added to the platform.

For Eli Lilly however we will make it really easy for you with previews of two leading Eli Lilly Narratives:

First is a bullish view that sees Eli Lilly stock as still offering upside from here. Second is a more cautious view that frames today’s price as already baking in demanding expectations. Use them as reference points to decide which set of assumptions feels closer to your own.

Fair value in this bullish Narrative: US$1,189.18 per share.

Implied discount to this fair value at the last close of US$1,122.50: about 5.6% undervalued.

Revenue growth assumption in this Narrative: 20% per year.

• GLP 1 drugs, led by Mounjaro and Zepbound, are treated as the key growth engine, supported by patent protection on tirzepatide out toward 2036 and expectations for wider insurance coverage.
• The author sees current production capacity as the main bottleneck, with large investment in new manufacturing plants expected to help increase volumes and potentially lower unit costs over time.
• The valuation hinges on several years of 20% to 25% revenue growth and a 9% discount rate, which together point to fair value a little above US$1,200 in the model used.

Fair value in this bearish Narrative: US$899.73 per share.

Implied premium to this fair value at the last close of US$1,122.50: about 24.8% overvalued.

Revenue growth assumption in this Narrative: 12.33% per year.

• This view leans heavily on risks around U.S. and international drug pricing reform, with concerns that future rules and discounts could pressure pricing for Eli Lilly’s obesity and diabetes portfolio.
• It highlights the company’s reliance on a small group of GLP 1 products and the possibility that competition, patent expiry and safety or efficacy headlines may weigh on longer term growth and margins.
• The analysts behind this framework anchor on a fair value around US$900 using revenue, margin and P/E assumptions that sit toward the lower end of the broader analyst range, and see the current share price as relatively full against that backdrop.

Both Narratives use different revenue growth paths, margins and P/E assumptions to reach very different fair value estimates for Eli Lilly stock. The most useful next step is to compare their key assumptions with your own expectations for GLP 1 demand, pricing, competition and regulation, then decide which path feels more realistic for your portfolio and risk tolerance.

To see how these and other Narratives fit into the wider community view on Eli Lilly, and to track how projections evolve as new data comes through, it can help to review the full set of community Narratives and company analysis in one place.

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Eli Lilly on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Do you think there's more to the story for Eli Lilly? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.